Avibactam restores the susceptibility of aztreonam against clinical isolates of Stenotrophomonas maltophilia [PublishAheadOfPrint]

Stenotrophomonas maltophilia is an emerging opportunistic pathogen, classified by the World Health Organization as one of the leading multidrug resistant organisms in hospital settings. Discovery of novel compounds and/or combination therapies for S. maltophilia is urgent. We demonstrate the in-vitro efficacy of aztreonam-avibactam (ATM-AVI) against S. maltophilia, and kinetically characterize the inhibition of the L2 β-lactamase by avibactam. ATM-AVI overcomes aztreonam resistance in selected clinical strains of S. maltophilia, addressing an unmet medical need.

http://ift.tt/2vyQnjy